PDMR Dealings / Market Share sale

RNS Number : 5079Q

Oxford Biomedica PLC

26 February 2021

 

PDMR Dealings / Market Share sale

Oxford, UK - 26 February 2021:   Oxford Biomedica plc ("Oxford Biomedica" or "the Group") (LSE: OXB), a leading gene and cell therapy group, was informed on 24 February 2021, that Helen Stephenson-Ellis, Chief People Officer of the Group, exercised 1,266 DBP (2019) options at nil cost, and sold all the resulting shares at 992p. Following this transaction Helen Stephenson-Ellis holds 59,296 options and no shares in the Company.

The issued share capital of the Group is 82,381,687 ordinary 50p shares.

The below notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail of the number of Ordinary Shares sold.

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Helen Stephenson-Ellis
2.	Reason for the notification
a)	Position/status	Chief People Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Exercise of options
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) Nil 1,266
e)	Aggregated information -  Aggregate volume -  Price -  Aggregated total	1,266 Nil Nil
f)	Date of the transaction	2021-02-24
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	Helen Stephenson-Ellis
2.	Reason for the notification
a)	Position/status	Chief People Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Disposal
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £9.92  1,266
e)	Aggregated information -  Aggregate volume -  Price -  Aggregated total	1,266 £9.917567 £12,555.64
f)	Date of the transaction	2021-02-24
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford Biomedica plc: Natalie Walter, Company Secretary	Tel: [phone]

About Oxford Biomedica

Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen, Beam Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a 3 year master supply and development agreement with AstraZeneca for large-scale manufacturing of the adenoviral based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 580 people. Further information is available at www.oxb.com

 

END

 

 

DSHSELFSMEFSELE